Neurocrine Biosciences Inc (STU:NB3)
€ 153.15 -1.9 (-1.23%) Market Cap: 15.37 Bil Enterprise Value: 14.57 Bil PE Ratio: 26.83 PB Ratio: 5.14 GF Score: 93/100

Neurocrine Biosciences Inc at Bank of America Global Healthcare Conference Transcript

May 12, 2026 / 06:20PM GMT
Release Date Price: €132.25 (+3.48%)
Tazeen Ahmad
Bank of America - Analyst

(audio in progress) analysts at the bank. It's my pleasure to have with me our next presenting company, Neurocrine. Sitting up here on stage, there are a couple of familiar faces, Matt Abernethy, who is, of course, Chief Financial Officer; as well as Todd Tushla, your job again, sir?

Todd Tushla
Neurocrine Biosciences Inc - Investor Relations

I'm still -- I'm the current Vice President of Investor Relations.

Tazeen Ahmad
Bank of America - Analyst

Okay. Just wanted to clarify.

Matthew Abernethy
Neurocrine Biosciences Inc - Chief Financial Officer

You did tell me this new title from you this morning is his favorite person. Can you confirm that?

Tazeen Ahmad
Bank of America - Analyst

We'll put that on your card. So maybe, Matt, for a few people who aren't as familiar with the company, can you just give us a quick overview of Neurocrine? And then we can go into some of the more recent

Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis
30-Year Financial on one screen
All-in-one Stock Screener with unlimited filters
Customizable Stock Dashboard
Real Time Insider Trading Transactions
8,000+ Institutional investors’ 13F holdings
Powerful Excel Add-in and Google sheets Add-on
All data downloadable
Quick customer support
And much more...
7-Day Free Trial · Cancel Anytime
Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot